Metered Dose Inhaler Errors Affect Many With COPD and Asthma

Pulmonology Advisor - In adults with COPD or asthma, two-thirds reported errors related to metered dose inhaler use. In reported step-by-step errors, ≥40% of patients failed to exhale fully and away prior to inhalation, to inhale slowly and deeply, or to hold their breath for a full 5 to 10 seconds. The findings of this review indicate the importance of educating patients on inhaler technique. Many of the errors are preventable by using nebulized therapy instead of a metered dose inhaler device. Read More →

Read More
Brea Neri
JAMA: Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease

JAMA - In this study of Medicare beneficiaries with Parkinson disease, of those who received antidementia treatment, nearly 45% experienced the never event of coadministration of a high-potency anticholinergic medication and an acetylcholinesterase inhibitor. Women and Hispanic beneficiaries as well as those living in the southern and midwestern US states were at highest odds of inappropriate dementia drug prescribing. Read More →

Read More
Brea Neri
ADA: Updated recommendations for the management of type 2 diabetes

ADA/EASD – Recommendations for the management of type 2 diabetes have been updated. New recommendations include: for patients with clinical cardiovascular disease, a SGLT2 inhibitor or a GLP-1 receptor agonist with proven cardiovascular benefit is recommended. For patients with CKD or clinical heart failure and ASCVD, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication. Read More →

Read More
Brea Neri
JAMA: Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD

JAMA - Among adults with COPD at high risk of exacerbation treated with inhaled corticosteroids, the addition of low-dose theophylline, compared with placebo, did not reduce the number COPD exacerbations over a 1-year period. The findings do not support the use of low-dose theophylline as adjunctive therapy to inhaled corticosteroids for the prevention of COPD exacerbations. Read More →

Read More
Brea Neri
U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD

Janssen - FDA has approved XARELTO® (rivaroxaban) to reduce the risk of major cardiovascular (CV) events, such as CV death, myocardial infarction (MI) and stroke, in people with chronic coronary or peripheral artery disease (CAD/PAD). XARELTO® is now the first and only Factor Xa inhibitor approved for patients living with these conditions. Read More →

Read More
Brea Neri
U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease

FDA - approved INVOKANA® (canagliflozin) to reduce the risk of major adverse cardiovascular (CV) events, including heart attack, stroke or death due to a cardiovascular cause in adults with type 2 diabetes (T2D) who have established CV disease. INVOKANA® is the first and only oral diabetes treatment approved with this indication. Read More →

Read More
Brea Neri
JAMA: Benefits and Harms of Antihypertensive Treatment in Low-Risk Patients With Mild Hypertension

JAMA - This prespecified analysis found no evidence to support guideline recommendations that encourage initiation of treatment in patients with low-risk mild hypertension (untreated blood pressure of 140/90-159/99 mm Hg). There was evidence of an increased risk of adverse events, which suggests that physicians should exercise caution when following guidelines that generalize findings from trials conducted in high-risk individuals to those at lower risk. Read More →

Read More
Brea Neri
REGENERON: FDA Approves Asthma Indication For DUPIXENT® (DUPILUMAB)

FDA - approved new indication for Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. It is the only asthma biologic that offers patient self-administration at home. Dupixent comes in two doses (200 mg and 300 mg) given every other week at different injection sites after an initial loading dose. Read More →

Read More
Brea Neri
FDA approves new drug to treat influenza

FDA - approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours. This is the first new antiviral flu treatment with a novel mechanism of action approved by the FDA in nearly 20 years. Read More →

Read More
Brea Neri
TherapeuticsMD Announces FDA Approval of TX-001HR: BIJUVA™ (Estradiol and Progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause

FDA – approved BIJUVA™ (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus. BIJUVA is expected to be available in pharmacies in the second quarter of 2019. Read More →

Read More
Brea Neri
JAMA: Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings

JAMA - Active pharmaceuticals continue to be identified in dietary supplements, especially those marketed for sexual enhancement, weight loss, or muscle building. The most common adulterants were sildenafil for sexual enhancement supplements, sibutramine for weight loss supplements, and synthetic steroids or steroid-like ingredients for muscle building supplements. The drug ingredients in these dietary supplements have the potential to cause serious adverse health effects. Read More →

Read More
Brea Neri